Vandetanib and the management of advanced medullary thyroid cancer

Current Opinion in Oncology

Volumn 25, Issue 1, 2013, Pages 39-43

  Campbell, Michael J ^a   Seib, Carolyn D ^a   Gosnell, Jessica ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Medullary thyroid cancer; Tyrosine kinase inhibitor; Vandetanib

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLACEBO; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MOLECULAR BIOLOGY; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; REVIEW; STEVENS JOHNSON SYNDROME; SUBARACHNOID HEMORRHAGE; THYROID MEDULLARY CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84871948951     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835a42b9     Document Type: Review

References (24)

1. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984; 63:319-342
2. Quayle FJ, Moley JF. Medullary thyroid carcinoma: Management of lymph node metastases. Curr Treat Options Oncol 2005; 6:347-354
3. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107:2134-2142
4. Scollo C, Baudin E, Travagli JP. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88:2070-2075
5. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association Task Force. Thyroid 2009; 19:565-612
6. Abraham DT, Low TH, Messina M. Medullary thyroid carcinoma: Longterm outcomes of surgical treatment. Ann Surg Oncol 2011; 18:219- 225
7. Brassard M, Rondeau G. Role of vandetanib in the management of medullary thyroid cancer. Biologics 2012; 6:59-66
8. Degrauwe N, Sosa JA, Roman S, et al. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 2012; 6:243- 252
9. Donis-Keller H, Dou S, Chi D, et al. Mutation in the RET proto-oncogene in multiple endocrine neoplasia type 2A. Hum Mol Genet 1993; 2:851- 856
10. Mulligan LM, Kwok JB, Healey CS, et al. A mutation in the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-460
11. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET protooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994; 367:375-376
12. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397
13. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006; 1:1002-1009
14. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-7290
15. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655
16. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767-772
17. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocr Metab 2010; 95:2664-2671
18. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134-141
19. Solomon B, Rischin D. Progress in molecular targeted therapy for thyroid cancer: Vandetanib in medullary thyroid cancer. J Clin Oncol 2012; 30:119- 121
20. Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009; 100:1777-1783
21. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and drug administration drug approval summary. Clin Cancer Res 2012; 18:3722-3730
22. Duplomb S, Benoit A, Mechtouff-Cimarelli L, et al. Unusual adverse event with vandetanib in metastatic medullary thyroid cancer. J Clin Oncol 2012; 30:E21-E23
23. Caprelsa (vandetanib) Food and Drug Administration Risk Evaluation and Mitigation Strategy. 2011. Accessed at http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvi ders/UCM253441.pdf
24. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis. PLoS One 2012; 7:e30353.